Anna Kazanchyan, MD | CEO, Saghmos Therapeutics – Cardiovascular and Kidney Protection with ST-62516

In this episode of Executive Insights for Life Sciences Innovators, we speak with Anna Kazanchyan, MD, CEO of Saghmos Therapeutics, about the company’s mission to revolutionize cardiovascular and kidney protection. We explore how their lead drug candidate, ST-62516, is designed to prevent Major Adverse Cardiac and Kidney Events (MACKE) in high-risk patients undergoing PCI. Dr. Kazanchyan discusses the science behind ST-62516, why it has a strong likelihood of FDA approval, and the company’s strategic approach to clinical trials, regulatory success, and market exclusivity.Learn more at genecoda.com.Originally recorded and streamed on YouTube Live on March 28, 2025.